BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bonacci M, Londoño MC, Esforzado N, Forns X, Sotoca JM, Campistol JM. Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list. Transpl Int 2015;28:1345-9. [PMID: 26073850 DOI: 10.1111/tri.12622] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76-139. [PMID: 27044763 DOI: 10.3350/cmh.2016.22.1.76] [Cited by in Crossref: 42] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
2 Ooka K, Lim JK. Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy. J Clin Transl Hepatol 2016;4:206-27. [PMID: 27777889 DOI: 10.14218/JCTH.2016.00017] [Reference Citation Analysis]
3 Villard C, Westman J, Frank J, Jynge O, Sparrelid E, Jorns C. The potential use of extended criteria donors and eligible recipients in liver transplantation for unresectable colorectal liver metastases in Central Sweden. Hepatobiliary Surg Nutr 2021;10:476-85. [PMID: 34430526 DOI: 10.21037/hbsn.2020.03.10] [Reference Citation Analysis]
4 Kamar N, Marion O, Rostaing L, Cointault O, Ribes D, Lavayssière L, Esposito L, Del Bello A, Métivier S, Barange K. Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation. Am J Transplant. 2016;16:1474-1479. [PMID: 26587971 DOI: 10.1111/ajt.13518] [Cited by in Crossref: 148] [Cited by in F6Publishing: 126] [Article Influence: 21.1] [Reference Citation Analysis]
5 Medeiros T, Rosário NF, Saraiva GN, Andrade TG, Silva AA, Almeida JR. Renal safety after one year of sofosbuvir-based therapy for chronic hepatitis C: A Brazilian "real-life" study. J Clin Pharm Ther 2018;43:707-13. [PMID: 29737025 DOI: 10.1111/jcpt.12697] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
6 Sasaki R, Kanda T, Yasui S, Haga Y, Nakamura M, Yamato M, Wu S, Nakamoto S, Arai M, Mikami S, Miyauchi H, Matsubara H, Yokosuka O. Successful Eradication of Hepatitis C Virus by Interferon-Free Regimens in Two Patients with Advanced Liver Fibrosis following Kidney Transplantation. Case Rep Gastroenterol 2016;10:248-56. [PMID: 27462193 DOI: 10.1159/000445374] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Belga S, Doucette KE. Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon. World J Gastroenterol 2016; 22(4): 1650-1663 [PMID: 26819530 DOI: 10.3748/wjg.v22.i4.1650] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
8 Aravinthan AD, Barbas AS, Doyle AC, Tazari M, Sapisochin G, Cattral MS, Ghanekar A, Mcgilvray ID, Selzner M, Greig PD, Bhat M, Selzner N, Grant DR, Lilly LB, Renner EL. Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study. Transpl Int 2017;30:1140-9. [DOI: 10.1111/tri.13008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
9 Cohen E, Liapakis A. Pharmacokinetics and important drug-drug interactions to remember when treating advanced chronic kidney disease patients with hepatitis C direct acting anti-viral therapy. Semin Dial 2019;32:141-51. [PMID: 30557903 DOI: 10.1111/sdi.12763] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
10 Fabrizi F, Martin P, Messa P. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. Kidney Int. 2016;89:988-994. [PMID: 27083277 DOI: 10.1016/j.kint.2016.01.011] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
11 Karkout KA, Al Sherif S, Hussein Q, Albawardi A, Boobes Y. Possible acute rejection associated with the use of the new anti-hepatitis C virus medications. Avicenna J Med 2019;9:32-4. [PMID: 30697524 DOI: 10.4103/ajm.AJM_171_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Perumpail RB, Hahambis TA, Aggarwal A, Younossi ZM, Ahmed A. Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol 2016; 8(1): 69-73 [PMID: 26783422 DOI: 10.4254/wjh.v8.i1.69] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]